Research Article
Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis
Table 1
Clinical characteristics and laboratory results in the AS and nr-axSpA patients.
| | AS group | nr-axSpA group |
| Age (mean ± SD, years) | 32.3 ± 8.21 | 34.4 ± 7.79 | Disease duration (mean ± SD, years) | 5.17 ± 3.55 | 4.98 ± 4.14 | ESR (mm/h) | 32.21 ± 16.97 | 34.58 ± 18.54 | CRP (mg/l) | 13.75 ± 8.61 | 13.11 ± 10.16 | BASDAI | 3.44 ± 1.11 | 4.20 ± 1.44 | BASFI | 46.87 ± 17.96 | 48.78 ± 18.85 | ASDAS | 1.72 ± 0.97 | 1.91 ± 0.96 | Calprotectin (ng/ml) | 15.30 ± 6.49 | 17.76 ± 8.59 | GSK-β (ng/ml) | 0.32 ± 0.02 | 0.53 ± 0.21 | β-catenin (ng/ml) | 1.69 ± 0.79 | 1.63 ± 0.65 | RUNX2 (ng/ml) | 0.28 ± 0.05 | 0.30 ± 0.07 | SPARCC | 5.60 ± 5.24 | 5.88 ± 5.72 | mSASSS | 18.57 ± 14.72 | 12.49 ± 11.48 |
|
|